NewcelX Ltd.(NCEL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NCEL Stock Analysis & AI Quality Score
AI stock analysis and institutional research for NewcelX Ltd. (NCEL), a Healthcare sector company. NCEL is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (FY 2025), NewcelX Ltd. reports net income of $-8.3M, free cash flow of $-2.8M. NCEL trades on the Nasdaq exchange and files with the SEC under CIK 1783036. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NCEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NewcelX Ltd. directly from SEC EDGAR.
Net Income
FY 2025
$-8.3M
Free Cash Flow
FY 2025
$-2.8M
D/E Ratio
FY 2025
0.05
AI Insight: NCEL Financial Trends
NewcelX equity recovered from -$9M deficit to $7M positive by Q4 2025, but lack of revenue data limits comprehensive trend analysis.
• Equity improved from -$9M in Q4 2023 to $7M in Q4 2025, recovering from deficit position.
• Total debt eliminated, falling from $3M in Q4 2024 to $0M in Q4 2025.
⚠ No revenue, profitability, or cash flow data available to assess operational performance trends.
AI Insight: NCEL Ratio Trends
Data is too sparse to identify meaningful trends, with only debt-to-equity ratios available showing dramatic deleveraging from 1.98 to 0.05.
• Debt-to-equity ratio plummeted from 1.98 in Q4 2024 to 0.05 in Q4 2025, indicating substantial deleveraging.
⚠ Critical profitability and returns metrics remain unavailable, limiting visibility into operational performance trends.
Get alerted when NCEL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NewcelX Ltd. including:
Top Institutional Holders of NCEL
CoreCap Advisors, LLC
$11.003 sh
| Fund | Value | Shares |
|---|---|---|
| CoreCap Advisors, LLC | $11.00 | 3 |
More Healthcare Companies
View all Healthcare →Put NCEL on your watchlist
Track score changes the day NewcelX Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NCEL a good stock to buy?
13F Pro's AI-powered analysis of NewcelX Ltd. (NCEL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NCEL are available on the NCEL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NCEL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NCEL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NewcelX Ltd.'s investment landscape.